Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2012; 18(42): 6060-6069
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6060
Table 1 New agents against hepatitis C virus currently evaluated in phase II or III trials
Drug | Company |
NS3/4A protease inhibitors | |
First generation, linear | |
Boceprevir (Approved) | MERCK |
Telaprevir (Approved) | JANSSEN |
Narlaprevir | MERCK |
First generation, macrocyclic | |
BI201335 | BOEHRINGER Ingelheim |
TMC435 | TIBOTEC/JANSSEN |
Danoprevir | ROCHE |
Vaniprevir | MERCK |
Asunaprevir | BRISTOL-MYERS SQUIBB |
ABT-450 | ABBOTT |
GS-9451 | GILEAD |
GS-9256 | GILEAD |
ACH-1625 | ACHILLION |
Second generation, macrocyclic | |
MK-5172 | MERCK |
Nucleos(t)ide analogue inhibitors of HCV polymerase | |
PSI/GS-7977 | PHARMASSET/GILEAD |
Mericitabine | ROCHE |
IDX-184 | IDENIX |
Non-nucleoside analogue inhibitors of HCV polymerase | |
Tegobuvir | GILEAD |
Filibuvir | PFIZER |
ANA-598/Setrobuvir | ANADYS/ROCHE |
BI207127 | BOEHRINGER Ingelheim |
ABT-333 | ABBOTT |
ABT-072 | ABBOTT |
VX-222 | VERTEX |
NS5A inhibitors | |
Daclatasvir | BRISTOL-MYERS SQUIBB |
GS-5885 | GILEAD |
GSK2336805 | GSK |
Cyclophilin inhibitors | |
Alisporivir1 | NOVARTIS |
SCY-635 | Scynexis |
- Citation: Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18(42): 6060-6069
- URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6060.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6060